X で紹介されていました。こんな薬も第2相に行きました。もともとパーキンソン病の治験薬ですが、α-シヌクレインが標的なので、FDAで許可されたそうです。 Inhibikase Therapeutics Announces FDA has Lifted the Full Clinical Hold on IkT-148009 in Multiple System Atrophy - Advancing model studies of IkT-148009 in MSA; early data has shown a substantial neuroprotective benefit in response to c-Abl inhibition…...www.inhibikase.com
Inhibikase Therapeutics Announces FDA has Lifted the Full Clinical Hold on IkT-148009 in Multiple System Atrophy - Advancing model studies of IkT-148009 in MSA; early data has shown a substantial neuroprotective benefit in response to c-Abl inhibition…...www.inhibikase.com
